SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT 1934
DATE OF REPORT: AUGUST 11, 2003
TITAN PHARMACEUTICALS, INC.
---------------------------
(Exact name of registrant as specified in charter)
DELAWARE 0-27436 94-3171940
---------------------------- ------------------------ ------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 244-4990
--------------
--------------------------------------------------------------------------------
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release dated August 11, 2003 - Titan Reports Second
Quarter 2003 Results
ITEM 9. REGULATION FD DISCLOSURE
In accordance with the interim guidance of the Securities and Exchange
Commission, the Company is furnishing the information required by Item 12 of
Form 8-K (Results of Operations and Financial Condition) under "Item 9
Regulation FD Disclosure" and information contained in this report (including
exhibits hereto) shall not be deemed "filed" for purposes of Section 18 of the
Exchange Act of 1934, as amended, or otherwise subject to the liability of that
section and shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended.
On August 11, 2003, the Company issued a press release announcing its
results of operations and financial condition for the three and six months ended
June 30, 2003. The full text of the press release is set forth in Exhibit 99.1
attached hereto.
2
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TITAN PHARMACEUTICALS, INC.
By: /s/ Robert E. Farrell
-------------------------------------------
Robert E. Farrell, Executive Vice President
and Chief Financial Officer
Dated: August 11, 2003
3
--------------------------------------------------------------------------------